Our progressive medicine to treat progressive illness.
Rigvir is a virus based immunomodulator with anti-tumoral response for the treatment of melanoma, local treatment of skin and subcutaneous metastases of melanoma, for prevention of relapse and metastases after radical surgery.
Rigvir is a live, non-pathogenic Picornaviridae family, Enterovirus genus, ECHO group, type 7 virus that has not been genetically modified.
Oncolytic virotherapy with Rigvir is a safe and effective cancer treatment, which improves time to progression, overall survival and the quality of life for cancer patients. Rigvir is well tolerated and causes few if any adverse effects.
Summary of Product Characteristics
Rigvir should be stored at -20°C (-4°F), transported frozen and thawed just before use.
From 2011 to 2019 Rigvir was fully reimbursed for residents of Latvia and over 70% of reimbursed melanoma patients have been treated with Rigvir.
The first Rigvir Guidelines on the Use in Oncology were released in 2006.
Download Guidelines
In 2015 Rigvir was included in the national guidelines for melanoma treatment in Latvia (EU).
Both pre-registration and post-registration studies have demonstrated a significant Rigvir response to many cancer types besides melanoma, for example, stomach and rectal cancer etc. as well as rare diagnoses.
The Rigvir has been shown to be effective against the following types of cancer:
Melanoma of several locations – skin, uterine cervix, eye, brain metastasis, adrenal gland, stomach, colorectal, pancreatic, uterine cervix, kidney, urinary bladder, ovarian, lung, prostate, breast, rima glottidis and several types of sarcoma: lymphosarcoma, angiosarcoma, reticulosarcoma, rhabdomyosarcoma as well as prevention of metastases (before/after surgery).
Rigvir virus finds and infects tumor cells. This process is called oncotropism. Subsequently, Rigvir replicates in tumor cells and destroys them. This process is called oncolysis. Both processes, oncotropism and oncolysis, are selective for tumor cells and healthy cells are only minimally affected, if at all. These processes stimulate immunity, both humoral and cellular. B and T cell activation increases several immune cells - B lymphocytes, CD8+, CD4+, CD38+, CD95+, as well as natural killer cells and monocytes/macrophages - thus helping the immune system to fight cancer.
The effect of Rigvir on isolated melanoma cell viability compared to control sample, at different times.